-
Mashup Score: 0MRD: Revolutionizing Lymphoma Care - [2023 SLIDES] - 7 month(s) ago
By: Allen Wilbanks Date: September 27,2023 In a recent presentation, Elizabeth Brem, MD shared her perspective on the utilization of minimal residual disease (MRD) technology in clinical trials and its potential to transform patient care. She emphasized the various applications of MRD, including its role in gui…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents - 7 month(s) ago
Blood Cancer Journal – Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Making MRD Assessment Work for AML | ASH Clinical News | American Society of Hematology - 8 month(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. Assessment of measurable residual disease (MRD) is more challenging and difficult to perform in acute myeloid leukemia (AML) than in chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL). The concept of MRD is the evolution of how clinicians try to measure and understand responses to therapy, explained Christopher Hourigan, DM, DPhil, a senior investigator at the National Heart, Lung, and Blood Institute of the
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1ASH Clinical News: September 2023 From the Desk Of... - 9 month(s) ago
Editor-in-Chief Aaron Gerds, MD, previews the forthcoming September 2023 issue of ASH Clinical News. Highlights include a feature article on the development …
Source: www.youtube.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia - 9 month(s) ago
In this review, we discuss the use of measurable residual disease (MRD) in AML, ALL, and chronic myeloid leukemia (CML). Our aims were to review the different methodologies for MRD assessment; describe the clinical relevance and medical decision making on the basis of MRD; compare and contrast the usage of MRD across AML, ALL, and CML; and discuss what patients need to know about MRD as it relates to their disease status and treatment. Finally, we discuss ongoing challenges and future directions with the goal of optimizing MRD usage in leukemia management.
Source: ascopubs.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0JNCCN 360 - MM - Bone Marrow Assessment of MRD as a Prognostic Tool in Multiple Myeloma - 11 month(s) ago
By: Joshua D. Madera, MS Posted: Thursday, June 1, 2023 For patients with multiple myeloma who received chimeric antigen receptor (CAR) T-cell therapy, continued early bone marrow evaluation of measurable residual disease (MRD) may serve as an efficacious prognostic tool, according to a study published in Blood Cancer…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Benefits of HSCT for Patients With AML With MRD After Initial Therapy - 11 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting in New York, New York, Andrew Artz, MD, participated in a debate about the benefits of hematopoietic stem cell transplantation among patients with AML with MRD after initial therapy.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Considering MRD Before HSCT for Patients With Acute Myeloid Leukemia - 12 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, Richard Stone, MD, debated the role of measurable residual disease when considering hematopoietic stem cell transplantation for patients with acute myeloid leukemia.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies #GDUHem meeting, Richard Stone, MD, discussed the role of #MRD when considering #HSCT for patients with #AML. Follow along as he shares his insights! https://t.co/tEPPqkhfge… @GreatDebatesCME @DanaFarber https://t.co/vYp7HN2MgQ
-
-
Mashup Score: 0
The Miami Myeloma MRD 2023 Virtual Meeting takes place on 6th April 2023 at 9am – 1pm EST This workshop is hosted by the Sylvester Comprehensive Cancer Center’s Myeloma Research Institute, in collaboration with the Multiple Myeloma Research Foundation (MMRF), the International Myeloma Foundation (IMF), and the HealthTree Foundation for Multiple Myeloma. VJHemOnc is pleased to be official media…
Source: ZoomCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Novel techniques being used for MRD assessment in AML & the importance of considering oligoclonality - 1 year(s) ago
Jacqueline Cloos, PhD, Amsterdam UMC, Amsterdam, The Netherlands, shares some insights into the importance of considering oligoclonality when assessing measurable…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Revolutionizing Lymphoma Care with MRD Technology. 🔬 @DrLizBrem 's insights on #MRD tech are revolutionizing #Lymphoma care! From CLL to CNS lymphoma, MRD is reshaping treatments.🚀 [video] https://t.co/C6oai2XAjV @_MDEducation @Ryan_Fitzpatric @UCIrvineHealth @HarvardMed https://t.co/k9t4x9qi0x